Familial hypercholesterolemia (FH) affects up to 1.3 million people in the United States, of whom 90% have not been properly diagnosed or treated. Many individuals with FH have no visible symptoms, and untreated, are at an excessively high risk of having an early heart attack—20 times higher. Early diagnosis and treatment are crucial to change these statistics.
The FH Foundation is a patient-centered nonprofit organization dedicated to education, advocacy, and research of all forms of FH. Their mission is to raise awareness and save lives by increasing the rate of early diagnosis and encouraging proactive treatment. The FH Awareness Tweet-a-Thon, which will focus on the signs, symptoms, and risks of FH, will take place Thursday, September 24 at 5 pm PST, 7 pm CST, and 8 pm EST. Join the conversation at: https.//twitter.com/TheFHFoundation. #KnowFH. Also, plan to join us at the 10th Annual CMHC #CMHC 2015 on October 21-24 and visit our booth at the CMHC Exhibitor Showcase to speak with representatives from the FH Foundation.
For further information on the residual risk of poorly controlled LDL-C, don’t miss our in-depth CME symposia at the 10th Annual CMHC featuring expert faculty: a Deep Dive Symposium will take place on Thursday evening, October 22 titled “Novel Therapies for LDL-C Lowering in the Fight Against Residual ASCVD Risk,” and will include lead investigator from the ODYSSEY Long-Term Study, Jennifer G. Robinson, MD, MPH. Our Clinical Advances Spotlight, “Advances in LDL Lowering: A Focus on PCSK9 Inhibitors’ Journey from Genetics to Clinical Practice,” will feature lead investigator from the OSLER studies, Marc S. Sabatine, MD.